C34 (CAS 40592-88-9): Selective TLR4 Inhibitor for Inflammatory Research

Executive Summary. C34 is a 2-acetamidopyranoside small molecule that selectively inhibits Toll-like receptor 4 (TLR4) signaling in inflammatory cells, with minimal off-target effects on TLR2 or TLR9 pathways (APExBIO product info). It is validated in vitro at 10 μM for suppression of TLR4-mediated pathways, and in vivo at 1 mg/kg for attenuating systemic inflammation in animal models (Chen et al., J Ethnopharmacol, 2025). C34 reduces TNFα and iNOS expression in human intestinal tissues, supporting its use in necrotizing enterocolitis and broader inflammatory signaling research. The crystalline compound is DMSO soluble and supplied at ≥98% purity with full analytical certification. Extensive evidence positions C34 as a benchmark tool in TLR4 pathway dissection and translational inflammation modeling.

Biological Rationale

Toll-like receptor 4 (TLR4) is a pattern recognition receptor essential for sensing Gram-negative bacterial lipopolysaccharide (LPS) and initiating innate immune responses. Aberrant TLR4 activation is implicated in the pathogenesis of sepsis, necrotizing enterocolitis, and neuroinflammatory diseases (CRISPRcasy review). Specific inhibition of TLR4 enables targeted modulation of cytokine cascades, allowing researchers to dissect mechanisms underlying acute and chronic inflammation. Small molecule TLR4 inhibitors are especially valuable in cellular models (macrophages, enterocytes) and translational animal studies.

Mechanism of Action of C34 (CAS 40592-88-9) TLR4 Inhibitor

C34 is chemically defined as (2R,3S,4R,5R,6S)-5-acetamido-2-(acetoxymethyl)-6-isopropoxytetrahydro-2H-pyran-3,4-diyl diacetate. It selectively binds to TLR4, preventing ligand-induced dimerization and downstream signaling through NF-κB and NLRP3 pathways. This blockade leads to reduced transcription of pro-inflammatory mediators, including TNFα and iNOS, particularly in macrophages and enterocytes. C34 exhibits negligible activity against TLR2 and TLR9, minimizing confounding off-target modulation. The compound is soluble in DMSO, facilitating cell-based and in vivo delivery (APExBIO).

Evidence & Benchmarks

• In vitro, C34 inhibits TLR4-mediated NF-κB signaling at ~10 μM in macrophage and enterocyte assays (product info).
• Systemic administration of C34 at 1 mg/kg reduces plasma pro-inflammatory cytokines in animal models of endotoxemia and necrotizing enterocolitis (Chen et al., 2025).
• C34 down-regulates both basal and LPS-induced TNFα and iNOS in ex vivo human intestinal tissue from necrotizing enterocolitis patients (APExBIO).
• Comparative studies show C34’s TLR4 selectivity exceeds that of many natural products, with minimal effect on TLR2 or TLR9 responses (Taxus chinensis extract comparison).
• In LPS-stimulated BV2 microglial cells, C34 achieves pathway inhibition comparable to leading anti-inflammatory extracts (Chen et al., 2025).

This article extends the mechanistic depth of C34 TLR4 Inhibitor: Selective Suppression in Inflammatory Pathways by integrating primary molecular and translational benchmarks. In contrast to C34 TLR4 Inhibitor: Precision Control in Necrotizing Enterocolitis Research, this dossier emphasizes comparative selectivity and best-practice protocol parameters for in vitro and in vivo use.

Applications, Limits & Misconceptions

C34 is optimized for experimental models that require precise, selective TLR4 inhibition. Key applications include:

• Dissecting inflammatory signaling in macrophages and enterocytes.
• Validating molecular hypotheses in necrotizing enterocolitis and sepsis models.
• Translational studies of TNFα and iNOS regulation in human tissues.
• Benchmarking natural product extracts against a synthetic, well-characterized TLR4 inhibitor.

Common Pitfalls or Misconceptions

• C34 is not a pan-TLR inhibitor; it does not significantly affect TLR2 or TLR9 signaling.
• Activity is concentration-dependent; sub-micromolar doses may be insufficient for pathway suppression in most cell types.
• Long-term storage of C34 solutions (especially in DMSO) leads to loss of potency; best used immediately after preparation.
• Evidence for efficacy in neuroinflammation is limited to preclinical models; clinical translation is not established (Chen et al., 2025).
• Off-target metabolic or immunomodulatory effects have not been extensively profiled; use appropriate controls in multi-pathway studies.

Workflow Integration & Parameters

• In vitro concentration: 10 μM C34 for suppression of TLR4-mediated signaling in macrophages or enterocytes is supported by product QC and literature benchmarks.
• In vivo dosing: 1 mg/kg via appropriate route (e.g., intraperitoneal), typically administered 1 hour before LPS or inflammatory challenge for optimal effect.
• Solution preparation: Dissolve C34 in DMSO to a stock concentration (e.g., 10 mM); dilute freshly into culture medium or vehicle for animal studies.
• Storage: Store crystalline C34 at -20°C. Avoid long-term storage of stock solutions; prepare working aliquots immediately before use.
• Controls: Use vehicle and TLR4 ligand (LPS) controls to confirm pathway specificity in each system.

Conclusion & Outlook

C34 (CAS 40592-88-9) is a validated, highly selective TLR4 inhibitor that enables precise dissection of inflammatory signaling in both cellular and animal models. Its robust selectivity and reproducible activity support its use as a gold-standard control in necrotizing enterocolitis and inflammatory research. While preclinical data highlight strong translational potential, further studies are warranted to map off-target effects and clinical applicability. As benchmarked in recent comparative studies (Chen et al., 2025), C34 provides clear mechanistic resolution for researchers interrogating the TLR4 axis and its role in disease.